Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289509 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01289509 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 42 participants.
The verdict
NCT01289509, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative bioavailability (BA) of two lots of E5501 40 mg tablets administered twice as single oral doses to healthy subjects.
Interventions
- DRUG E5501
- DRUG Drug: E5501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01289509
The ClinicalTrials.gov registry entry for NCT01289509 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which E5501 is the first listed.
NCT01289509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01289509 about?
NCT01289509 is a clinical study titled "A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects". The purpose of this study is to evaluate the relative bioavailability (BA) of two lots of E5501 40 mg tablets administered twice as single oral doses to healthy subjects.
What is the current status of trial NCT01289509?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2010-12. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01289509?
The interventions under investigation include: E5501 (DRUG), Drug: E5501 (DRUG).
Who is sponsoring clinical trial NCT01289509?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.